Group items matching

in title, tags, annotations or url

NIDDK requests applications to join a new research consortium "Microphysiological Systems (MPS) for Modeling Diabetes (MPS-MOD)". NIDDK will support the development and validation of human tissue chips that closely mimic the normal physiology of key metabolic tissues, including the pancreatic islet, liver, skeletal muscle, and white adipose tissue (WAT). Experimental designs for the MPS-MOD platforms should incorporate strategies to measure pathophysiological changes associated with metabolic disease, including the impact of immune cells on metabolic dysfunction. Once developed, these multi-dimensional MPS-MOD platforms will serve as the foundation for NIDDK's advanced strategy to identify new and novel therapeutics for diabetes. The utility and validity of model systems developed under this initiative will be measured, in part, through the ability of known diabetes therapeutic agents and biomarkers to influence biology of the system, using best practices and rigorous study design. The need for high-quality, well-characterized isogenic/patient derived iPSC (induced pluripotent stem cell) lines and standardized differentiation procedures is a critical step in turning disease-specific lines into tools for discovery. In the future, iPSC-based human tissue chips could play a central role in drug development, testing, screening, drug repurposing and toxicity testing.

The purpose of this FOA is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.

The purpose of this Funding Opportunity Announcement (FOA) is to support research to deepen our knowledge of the use of synthetic psychoactive drugs, their mechanisms of action, their health effects, and development of prevention strategies and strategies to treat patients in emergency departments and long range treatment.

The MPS DC is expected to be the central clearinghouse for TC data management, and will incorporate novel approaches and technologies for data management, data mining and meta-analyses, and data sharing across many organs and tissues, diseases, data types, and TC platforms. The MPS Data center is expected to provide different levels of public and tiered access to TC information for basic and clinical researchers, academic and practicing physicians, the pharmaceutical industry, NIH, FDA and other government agencies, patients, and the lay public. The MPS Data Center will work with IQ Consortium members to develop and make available a secure, customizable coordinated data management system for collection, storage, and analyses of diverse data types from multiple TC platforms being developed and used for drug screening, safety and efficacy testing.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of integrated symptom monitoring and management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative established to accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): the Implementation of Integrated and Evidenced-based Symptom Management Throughout the Cancer Trajectory. The purpose of this specific FOA is to promote research on the implementation and evaluation of comprehensive symptom management systems for use in cancer care delivery through a Research Consortium. This research will provide new insights and valuable evidence that can be used to guide efforts on a nation-wide basis to improve symptom control for cancer patients during treatment and survivorship.

Support to patients with primary sclerosing cholangitis, an autoimmune disease that causes the bile ducts inside and outside the liver to become scarred, narrowed, and eventually blocked, as well as their families and caregivers, and to raise funds for research on the causes, treatments, and a cure for PSC. To that end, the foundation offers grants of up to $60,000 over two years tor research projects that address an important and novel, basic, or clinical research question related to PSC and closely allied diseases (such as inflammatory bowel diseases, ulcerative colitis, or Crohn's disease).

As part of this mission, the foundation is seeking applications for scientific research projects with the potential to significantly advance the field toward an effective understanding of the mechanisms of cerebrovascular disease. TAAF grants respond to the cerebrovascular community's need for projects that highlight innovative research strategies that will support the development of novel cerebrovascular therapies, clinical management, and recovery for patients.

This Funding Opportunity Announcement (FOA) issued by the Fogarty International Center (FIC) seeks to stimulate innovative ideas and impactful research to better understand the complexities around developing appropriate approaches for effective diagnosis, prevention, therapeutic interventions and integrated clinical care for HIV-associated non-communicable diseases (NCDs) in Low and Middle-Income Countries (LMICs). Specifically, this initiative will support research in the following areas: a) Basic sciences to address etiopathogenesis of NCDs in Persons Living with HIV (PLWH); b) Aging process in PLWH; c) Diagnostics tools for early detection of NCDs in PLWH; d) Therapeutic interventions to explore optimal drug regimens for PLWH with NCDs; e) Behavioral studies for better quality of life of PLWH with NCDs; and f) Clinical studies for better patient centered care for PLWH with NCDs. The R21 grant mechanism is intended to encourage exploratory/developmental research by providing support for the early and conceptual stages of project development and assessing feasibility of the proposed studies (https://grants.nih.gov/grants/funding/r21.htm ). It is hoped that this preliminary research will lay the foundation for larger studies that can lead to applications to other organizations or NIH institutes that support HIV-associated NCD research.

This Funding Opportunity Announcement (FOA) solicits renewal applications for Biobanks that will support the following NCI clinical trial programs: The NCI National Clinical Trials Network (NCTN; https://research.usc.edu/nci-national-clinical-trials-network-nctn-program/), and NCI Community Oncology Research Program (NCORP). The NCTN Biospecimen Bank (also referred to as NCTN Biobanks) will be responsible for collecting, processing, storing, and distributing well-annotated human specimens from patients with cancer who are participating in NCI-funded NCTN Phase II-III and other clinical treatment trials (CTEP/Division of Cancer Treatment and Diagnosis; DCTD). The main goal is to support NCTN with the state-of the-art banking infrastructure and operations including maintenance of up-to-date specimen inventory. The NCTN Biobanks will distribute to qualified investigators the biospecimens linked to high-quality clinical data (including treatment and outcome information) that are critical for developing and validating biomarkers for cancer diagnosis, prognosis and prediction of responses to therapy. The NCTN Biobanks will work in collaboration with NCTN Groups and Group Statistical and Data Management Centers as well as affiliated institutions to ensure effective operation. Each Biobank needs to maintain association with one specific NCTN Group and needs to be endorsed in that role by the group leaders. NCTN Biobanks will also support biobanking and storage of biospecimens from NCORP cancer control and prevention trials (NCORP/Division of Cancer Prevention; DCP).

The main goal of this limited competition Funding Opportunity Announcement (FOA) is to continue the state-of the-art biobanking infrastructure and operations for early-stage and experimental clinical trials sponsored by the National Cancer Institute (NCI). The biobanking needs of the following NCI clinical trial programs will be supported: Experimental Therapeutics Clinical Trials Network (ETCTN), and Other NCI-supported early and experimental trials. Currently, this biobanking infrastructure supporting NCI early experimental clinical trials is part of a biobank serving primarily another NCI program, National Clinical Trials Network (NCTN). Through a separate U24 award under this FOA, the NCI aims to separate the existing ETCTN-serving biobanking infrastructure and operation from the current NCTN Biobank. This separated entity will be termed: Early-Phase and Experimental Clinical Trials Biospecimen Bank (also referred to as EET Biobank). Although the EET Biobank and the "parent" NCTN Biobank may be hosted in the same institution, they are expected to become independent operations with separate leaderships. EET Biobank will be responsible for collecting, processing, storing a variety of human specimens from patients with cancer who are participating in NCI-funded ETCTN and other NCI-supported early and experimental clinical trials. The responsibilities of EET Bank will also include maintenance of up-to-date specimen inventory and specimen distribution to qualified NCI-approved trial investigators and research laboratories.

This Funding Opportunity Announcement (FOA) invites applications for a CHR Data Processing, Analysis and Coordination Center (DPACC) to support and extend the work of the proposed Clinical High Risk for Psychosis Research Network to be funded under RFA-MH-20-340 . The DPACC will provide oversight and coordination of two parallel lines of inquiry: 1) The aggregation of extant CHR-related data sets and subsequent secondary analyses for refinement of multi-modal biomarkers and development of biomarker algorithms that predict individual clinical trajectory and outcomes and 2) The management, direction, and overall coordination, including data processing and analysis, for a new multi-site network(s) focused on dissecting the heterogeneity of the CHR syndrome. Toward achieving the first goal, the DPACC - in conjunction with NIMH and external working groups - will identify appropriate extant CHR data sets, aggregate and harmonize the data through development of a standardized processing and analysis pipeline for each data type, upload the data to the NIMH Data Archive (NDA), use computational techniques to identify and validate biomarker algorithms and/or risk calculators that predict the clinical trajectories and outcomes for individual patients, and establish a curated public data set that will serve as a resource for the research community.

The FY19 VRP IIRA is intended to support studies that will yield highly impactful discoveries or major advancements in the research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma. Research projects may focus on any phase of research (e.g., basic, translational, applied, clinical, observational), excluding clinical trials. The research idea or solution should be innovative or novel, or a significant advancement over existing ideas or solutions, as applicable.

The Tourette Association of America (TAA) aims to encourage early career researchers to invest their efforts and expertise in increasing our biological understanding of Tourette Syndrome (TS), pursing clinical research aimed at improving patient care, and developing and testing new therapies.

The research that we fund is vital to our mission of understanding the role of diet, nutrition, body composition and physical activity in reducing cancer risk and improving outcomes for cancer patients and survivors. Our Research Grant Program builds on and is informed by the scientific findings from our Continuous Update Project and Third Expert Report.

Baxter's Young Investigator Awards seek to stimulate and reward research applicable to the development of therapies and medical products that save and sustain patients' lives. We invite current graduate students and postdoctoral fellows to submit descriptions of ongoing research. The Baxter Young Investigator Awards program consists of two tiers: first-tier awards include a $3,000 cash prize and an onsite visit to Baxter to present the award-winning research; second-tier awards receive a $500 cash prize. Prizes are granted based on merit of the research.

Applications will be accepted for a broad range of melanoma research projects involving basic science, clinical trials, etc. 1. An adequate discussion of biostatistics is required, including but not limited to specification of numbers of cell lines, laboratory animals, or patients to be treated in the studies. 2. Plans for adjustment for multiple looks should be presented, particularly in regards to clinical endpoints and evaluation of multiple biomarkers.

The objective of the AGA Research Foundation Research Scholar Award (RSA) is to support early-career investigators working toward independent and productive research careers in digestive diseases by ensuring that a major proportion of their time is protected for research (i.e., a minimum of 75 percent effort dedicated to the proposed project). This award will support junior faculty (not fellows) who have demonstrated exceptional promise and have some record of accomplishment in research pertaining to celiac disease. Projects must focus on the pathophysiology, epidemiology, prevention, diagnosis, treatment or patient outcomes of celiac disease.

Through the program, grants of between $50,000 and $150,000 will be awarded to early-career investigators in support of novel research proposals that seek to advance the medical knowledge of migraine. Eligible research includes non-interventional clinical research, with a focus on early diagnosis and treatment, epidemiology, and Patient Reported Outcomes (PRO)/Quality of Life (QoL) measures; biomarkers for diagnosis and prognosis; and preclinical research focused on mechanism of disease (non-calcitonin gene-related peptide [CGRP]- and non-pituitary adenylate cyclase-activating polypeptide [PACAP]-related).

We encourage innovators to submit potentially ground-breaking ideas in perinatal care, including a particular interest in the following areas:  - Consumer Healthcare  - Community Health Approaches - Health Technologies  - Medical Devices  - Patient Care - Pharmaceuticals - Cross-sector Initiatives   Priority will be given to science-based potential innovations backed by data.  Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation. Please keep in mind that no idea is too big or too early for consideration. The goal of the Maternal Health QuickFire Challenge is to discover solutions aimed to help mothers survive and prevent adverse consequences from pregnancy and childbirth.  These potential solutions should be meet the below outlined criteria. The submitted potential solution must be either be pioneering or evidence based. Please provide data supporting the theory of change or the intervention accordingly. Submitted ideas must meet at least three of the below criteria: - Actionable - is the project achievable? - Measurable in terms of health impact - Filling a current data gap - Proven sustainability or strong rationale for a sustainable business model - Scalable